Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Nov 5 (Reuters) - Intra-Cellular Therapies ITCI.O said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Savio D'Souza) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Intra-Cellular Therapies
See all newsBrief: Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court
Intra-Cellular Therapies Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Apple, Caterpillar, Visa
Street View: New drug launches, ITCI deal to boost J&J's growth
J&J beats quarterly sales and profit estimates on cancer drug sales (updated)